Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobulin treatment: a case study in Zhejiang Province, East China.

Zeng Y, Luo M, Lin J, He H, Deng X, Xie S, Fang Y.

Hum Vaccin Immunother. 2019 Nov 26:1-10. doi: 10.1080/21645515.2019.1688031. [Epub ahead of print]

PMID:
31769718
2.

[Economic evaluation on strategy for preventing mother-to-child transmission of hepatitis B in Zhejiang Province].

Zeng YB, Luo ML, He HQ, Deng X, Xie SY, Fang Y.

Zhonghua Yu Fang Yi Xue Za Zhi. 2019 Jul 6;53(7):706-712. doi: 10.3760/cma.j.issn.0253-9624.2019.07.010. Chinese.

PMID:
31288342
3.

Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China.

Jia Y, Li L, Cui F, Zhang D, Zhang G, Wang F, Gong X, Zheng H, Wu Z, Miao N, Sun X, Zhang L, Lv J, Yang F.

Hum Vaccin Immunother. 2014;10(10):2983-91. doi: 10.4161/hv.29944.

4.

Cost-effectiveness of active-passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection.

Fan L, Owusu-Edusei K Jr, Schillie SF, Murphy TV.

Hepatology. 2016 May;63(5):1471-80. doi: 10.1002/hep.28310. Epub 2015 Dec 23.

PMID:
26509655
5.

Economic evaluation of universal newborn hepatitis B vaccination in China.

Lu SQ, McGhee SM, Xie X, Cheng J, Fielding R.

Vaccine. 2013 Apr 3;31(14):1864-9. doi: 10.1016/j.vaccine.2013.01.020. Epub 2013 Feb 4.

PMID:
23384752
6.

Cost-effectiveness of antiviral prophylaxis during pregnancy for the prevention of perinatal hepatitis B infection in South Korea.

Lee D, Shin HY, Park SM.

Cost Eff Resour Alloc. 2018 Feb 15;16:6. doi: 10.1186/s12962-018-0088-9. eCollection 2018.

8.

Cost-effectiveness analysis of hepatitis B vaccine booster in children born to HBsAg-positive mothers in rural China.

Wang Y, Shi JF, Wang L, Yan Y, Yao H, Dai M, Chen T, Qu C.

Int J Infect Dis. 2019 Jan;78:130-139. doi: 10.1016/j.ijid.2018.08.024. Epub 2018 Nov 19.

9.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

10.

Strategies for the prevention of perinatal hepatitis B transmission in a marginalized population on the Thailand-Myanmar border: a cost-effectiveness analysis.

Devine A, Harvey R, Min AM, Gilder MET, Paw MK, Kang J, Watts I, Hanboonkunupakarn B, Nosten F, McGready R.

BMC Infect Dis. 2017 Aug 9;17(1):552. doi: 10.1186/s12879-017-2660-x.

11.

Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B.

Hutton DW, Tan D, So SK, Brandeau ML.

Ann Intern Med. 2007 Oct 2;147(7):460-9.

PMID:
17909207
12.

Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobin treatment.

Chen SC, Toy M, Yeh JM, Wang JD, Resch S.

Pediatrics. 2013 Apr;131(4):e1135-43. doi: 10.1542/peds.2012-1262. Epub 2013 Mar 25. Erratum in: Pediatrics. 2014 Feb;133(2):346.

13.

[Cost-effectiveness and cost-benefit analysis on strategy for preventing mother-to-child transmission of hepatitis B virus].

Cai YL, Zhang SX, Yang PC, Lin Y.

Zhonghua Liu Xing Bing Xue Za Zhi. 2016 Jun;37(6):846-51. doi: 10.3760/cma.j.issn.0254-6450.2016.06.021. Chinese.

PMID:
27346114
14.

Cost-effectiveness of testing hepatitis B-positive pregnant women for hepatitis B e antigen or viral load.

Fan L, Owusu-Edusei K Jr, Schillie SF, Murphy TV.

Obstet Gynecol. 2014 May;123(5):929-37. doi: 10.1097/AOG.0000000000000124.

15.

[Cost-effectiveness and affordability of strategy for preventing mother-to-child transmission of hepatitis B in China].

Lin Y, Zhang SX, Yang PC, Cai YL, Zou YH.

Zhonghua Liu Xing Bing Xue Za Zhi. 2017 Jul 10;38(7):852-859. doi: 10.3760/cma.j.issn.0254-6450.2017.07.003. Chinese.

PMID:
28738455
16.
17.

[Cost-effectiveness of community-based treatment of chronic hepatitis B in China].

Zhang SX, Yang PC, Cai YL, Lin Y, Zou YH.

Zhonghua Liu Xing Bing Xue Za Zhi. 2017 Jul 10;38(7):860-867. doi: 10.3760/cma.j.issn.0254-6450.2017.07.004. Chinese.

PMID:
28738456
18.

Cost-effectiveness of antiviral treatment after resection in hepatitis B virus-related hepatocellular carcinoma patients with compensated cirrhosis.

Xie L, Yin J, Xia R, Zhuang G.

Hepatology. 2018 Oct;68(4):1476-1486. doi: 10.1002/hep.29922. Epub 2018 May 14. Review.

PMID:
29633304
19.

[Cost-utility analysis on universal childhood hepatitis A vaccination in regions with different anti-HAV prevalence rates of China].

Pan XJ, Feng YM, Zhuang GH.

Zhonghua Liu Xing Bing Xue Za Zhi. 2012 Aug;33(8):862-6. Chinese.

PMID:
22967346
20.

An economic evaluation of the current measles vaccination program: A case study in Zhejiang Province, east China.

Zeng Y, Luo M, Chen J, He H, Deng X, Xie S, Fang Y.

Vaccine. 2019 May 21;37(23):3071-3077. doi: 10.1016/j.vaccine.2019.04.057. Epub 2019 Apr 27.

PMID:
31040084

Supplemental Content

Support Center